This page contains brief information about abiraterone acetate (Yonsa, Zytiga) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Abiraterone acetate is approved to be used with prednisone to treat:
- Prostate cancer that has metastasized (spread to other parts of the body). It is used:
- In patients whose cancer is castrate resistant (has not responded to treatments that lower testosterone levels). This use is approved for the Zytiga brand name of abiraterone acetate.
- With methylprednisolone in patients whose cancer is castrate resistant. This use is approved for the Yonsa brand name of abiraterone acetate.
- In patients whose cancer is high-risk and castrate sensitive (has responded to treatments that lower testosterone levels). This use is approved for the Zytiga brand name of abiraterone acetate.
Abiraterone is also being studied in the treatment of other types of cancer.
More About Abiraterone Acetate
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Abiraterone Acetate - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Hormone Therapy for Prostate Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Abiraterone Acetate - Check for trials from NCI's list of cancer clinical trials now accepting patients.